Hospital
Covenant Medical Center, INC.
Covenant Medical Center, INC. was paid $96.77M by Medicaid between Jan 2018 and Dec 2024, across 583 billing codes. Its largest line is 99285, emergency room visit (most serious) — 26% of everything it billed.
33Billing provider infoCOVENANT MEDICAL CENTER, INC.
SAGINAW, MI 48602
SAGINAW, MI 48602
33aNPI1588656946assigned 08/21/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$96.77M
24GClaims3,505,827
24DCodes billed583
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Michigan
Rank by total paid#10 of 86
Median peer was paid$21.55M
This provider vs. median4.5×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 430,608 | $13.51M | |
| 2019 | 553,962 | $14.68M | |
| 2020 | 455,377 | $12.03M | |
| 2021 | 565,612 | $15.35M | |
| 2022 | 543,631 | $14.77M | |
| 2023 | 528,051 | $14.04M | |
| 2024incomplete | 428,586 | $12.39M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 26% | 80,146 | 72,191 | $25.64M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 21% | 110,819 | 102,035 | $20.64M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 3.1% | 36,256 | 31,348 | $3.04M |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | 2.3% | 4,909 | 4,524 | $2.24M |
| G0378 | Hospital observation service, per hour | 2.2% | 15,414 | 14,795 | $2.10M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 2.0% | 16,262 | 15,864 | $1.94M |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.8% | 5,571 | 5,253 | $1.72M |
| 82947 | 1.7% | 43,012 | 28,438 | $1.67M | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 1.5% | 47,781 | 12,528 | $1.49M |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.5% | 44,736 | 33,211 | $1.47M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.3% | 62,625 | 18,513 | $1.26M |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | 1.3% | 2,691 | 2,557 | $1.26M |
571 more codes
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 1.2% | 16,392 | $1.17M |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.1% | 15,067 | $1.07M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.1% | 8,832 | $1.03M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.0% | 24,840 | $990K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 11,552 | $950K |
| 80061 | Lipid panel | <1% | 34,319 | $913K |
| 71045 | Radiologic examination, chest; single view | <1% | 25,533 | $834K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 5,465 | $799K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 35,624 | $795K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 23,868 | $737K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 11,938 | $728K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 1,577 | $714K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 12,304 | $707K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 31,899 | $629K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 5,772 | $550K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 13,728 | $542K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 1,452 | $522K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 8,913 | $510K |
| 59025 | Fetal non-stress test | <1% | 5,826 | $475K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 3,649 | $458K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 32,753 | $452K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 32,276 | $444K |
| 47562 | <1% | 170 | $425K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 8,547 | $398K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 7,856 | $379K |
| 76830 | Ultrasound, transvaginal | <1% | 6,850 | $375K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 2,057 | $368K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 4,885 | $335K |
| 58661 | <1% | 124 | $314K | |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 480 | $299K |
| 76770 | <1% | 5,695 | $297K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 3,946 | $287K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 3,406 | $268K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 2,216 | $263K |
| 95816 | <1% | 2,437 | $258K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 17,897 | $251K |
| 97162 | <1% | 5,746 | $249K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 2,154 | $242K |
| 80053 | Comprehensive metabolic panel | <1% | 143,028 | $237K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 45,820 | $230K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 2,167 | $228K |
| 97161 | <1% | 4,862 | $226K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 17,418 | $217K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 2,442 | $212K |
| 93458 | <1% | 241 | $204K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 16,823 | $203K |
| 92526 | <1% | 4,759 | $200K | |
| 76801 | <1% | 3,462 | $195K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 4,660 | $185K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 164,101 | $182K |
| 93971 | <1% | 3,811 | $181K | |
| 72141 | <1% | 1,415 | $167K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 3,023 | $157K |
| 93970 | <1% | 1,608 | $148K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 3,950 | $141K |
| 94060 | <1% | 1,175 | $139K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 23,119 | $138K |
| 64400 | <1% | 1,058 | $133K | |
| 76642 | <1% | 3,548 | $130K | |
| 76536 | <1% | 2,729 | $128K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 23,200 | $124K |
| 95811 | <1% | 313 | $123K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 7,420 | $122K |
| 36415 | Collection of venous blood by venipuncture | <1% | 236,161 | $117K |
| 87480 | <1% | 22,302 | $116K | |
| 87660 | <1% | 22,302 | $116K | |
| 86900 | <1% | 16,923 | $113K | |
| 58571 | <1% | 27 | $113K | |
| 87510 | <1% | 21,804 | $108K | |
| 10061 | <1% | 651 | $107K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 8,336 | $100K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 1,147 | $98K |
| 92523 | <1% | 886 | $98K | |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 2,795 | $95K |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 3,899 | $90K |
| 43235 | <1% | 299 | $89K | |
| 73221 | <1% | 747 | $89K | |
| 58558 | <1% | 77 | $87K | |
| 97597 | <1% | 1,122 | $87K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 21,426 | $86K |
| C8928 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, during rest and cardiovascular stress test using treadmill, bicycle exercise and/or pharmacologically induced stress, with interpretation and report | <1% | 766 | $84K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 962 | $84K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 65,887 | $83K |
| 29799 | <1% | 1,298 | $83K | |
| 96367 | <1% | 3,031 | $83K | |
| 70496 | <1% | 713 | $82K | |
| 76881 | <1% | 1,505 | $82K | |
| 97166 | <1% | 1,734 | $80K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 533 | $79K |
| 95913 | <1% | 306 | $76K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 4,625 | $76K |
| 83970 | <1% | 5,068 | $75K | |
| 95782 | <1% | 150 | $75K | |
| 36430 | <1% | 569 | $71K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 7,929 | $67K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 15,892 | $67K |
| 71250 | <1% | 1,433 | $66K | |
| 77065 | Tomosynthesis, mammo | <1% | 1,673 | $66K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 2,500 | $63K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 38,239 | $63K |
| 96415 | <1% | 1,366 | $62K | |
| G0145 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision | <1% | 4,960 | $61K |
| Q5104 | Injection, infliximab-abda, biosimilar, (renflexis), 10 mg | <1% | 71 | $61K |
| 77066 | Tomosynthesis, mammo | <1% | 1,141 | $61K |
| 97165 | <1% | 1,377 | $58K | |
| 95909 | <1% | 408 | $56K | |
| 93017 | <1% | 3,053 | $56K | |
| 73564 | <1% | 3,938 | $55K | |
| 95910 | <1% | 422 | $54K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 259 | $54K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 915 | $53K |
| 97116 | <1% | 4,222 | $52K | |
| 70491 | <1% | 583 | $52K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 4,327 | $51K |
| 74178 | <1% | 379 | $51K | |
| 72110 | <1% | 2,690 | $51K | |
| 74019 | <1% | 5,176 | $51K | |
| 29515 | <1% | 764 | $50K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 31,028 | $49K |
| 71271 | <1% | 917 | $49K | |
| 86780 | <1% | 7,263 | $49K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 41,865 | $48K |
| 82728 | <1% | 9,432 | $46K | |
| 36591 | <1% | 2,745 | $46K | |
| 87481 | <1% | 3,886 | $45K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 9,591 | $44K |
| 88342 | <1% | 8,567 | $42K | |
| 96417 | <1% | 1,101 | $42K | |
| 82607 | <1% | 8,257 | $41K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 744 | $41K |
| 76870 | <1% | 1,575 | $40K | |
| 99233 | Hospital visit by a doctor, follow-up day (complex) | <1% | 816 | $40K |
| 94726 | <1% | 1,955 | $38K | |
| 84439 | <1% | 13,616 | $38K | |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 584 | $34K |
| 87653 | <1% | 3,146 | $34K | |
| 85027 | <1% | 19,736 | $33K | |
| 84702 | <1% | 10,853 | $32K | |
| 80074 | <1% | 1,733 | $31K | |
| 83550 | <1% | 8,951 | $30K | |
| 77336 | <1% | 559 | $30K | |
| 77080 | <1% | 541 | $29K | |
| 76882 | <1% | 667 | $29K | |
| 73030 | <1% | 4,215 | $28K | |
| 70486 | <1% | 1,272 | $28K | |
| 82746 | <1% | 5,846 | $27K | |
| 99223 | Prolong inpt eval add15 m | <1% | 272 | $27K |
| 19083 | <1% | 39 | $26K | |
| 77412 | <1% | 230 | $26K | |
| J2505 | Injection, pegfilgrastim, 6 mg | <1% | 19 | $25K |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 2,466 | $25K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 2,764 | $24K |
| 99239 | Hospital discharge day management, more than 30 minutes | <1% | 456 | $24K |
| 87507 | <1% | 250 | $24K | |
| 87186 | <1% | 11,173 | $24K | |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 275 | $24K |
| 83540 | <1% | 9,156 | $23K | |
| 74018 | <1% | 2,252 | $22K | |
| 97022 | <1% | 4,055 | $22K | |
| 90670 | <1% | 141 | $21K | |
| 82043 | <1% | 8,549 | $21K | |
| 73130 | <1% | 3,797 | $20K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 261 | $20K |
| 73630 | <1% | 4,075 | $19K | |
| 99222 | Initial hospital care, per day, moderate complexity | <1% | 301 | $19K |
| 86803 | <1% | 3,730 | $19K | |
| 82570 | <1% | 10,385 | $19K | |
| 84403 | <1% | 1,569 | $19K | |
| 83735 | <1% | 43,936 | $18K | |
| 86480 | <1% | 683 | $18K | |
| 90686 | <1% | 1,315 | $18K | |
| 87340 | <1% | 5,540 | $18K | |
| 78227 | <1% | 75 | $18K | |
| 86140 | <1% | 30,523 | $16K | |
| 93880 | <1% | 232 | $16K | |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 158 | $16K |
| 81001 | <1% | 57,414 | $15K | |
| 72050 | <1% | 407 | $15K | |
| 86850 | <1% | 15,004 | $15K | |
| 73610 | <1% | 3,717 | $15K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 5,743 | $14K |
| 86038 | <1% | 2,809 | $14K | |
| 88341 | <1% | 2,035 | $14K | |
| 87077 | <1% | 6,523 | $14K | |
| 84146 | <1% | 2,664 | $14K | |
| 97163 | <1% | 318 | $13K | |
| 73502 | <1% | 1,937 | $13K | |
| 77334 | <1% | 44 | $13K | |
| 72072 | <1% | 701 | $13K | |
| 85610 | <1% | 20,989 | $13K | |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 399 | $12K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 1,070 | $12K |
| 88307 | <1% | 1,563 | $12K | |
| 73700 | <1% | 255 | $12K | |
| 87522 | Neg quan hep c or qual rna | <1% | 663 | $12K |
| 83516 | <1% | 1,150 | $12K | |
| 86762 | <1% | 3,026 | $12K | |
| 87070 | <1% | 5,044 | $12K | |
| 87081 | <1% | 6,298 | $12K | |
| 84481 | <1% | 1,697 | $12K | |
| 86003 | <1% | 299 | $11K | |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | <1% | 47 | $11K |
| 84153 | <1% | 1,432 | $11K | |
| 72100 | <1% | 350 | $11K | |
| 82248 | <1% | 7,535 | $11K | |
| 83001 | <1% | 1,247 | $11K | |
| 96523 | <1% | 617 | $11K | |
| 92610 | <1% | 409 | $11K | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 1,281 | $11K |
| 73110 | <1% | 2,283 | $11K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 1,429 | $10K |
| 87631 | <1% | 5,457 | $10K | |
| 83880 | <1% | 5,792 | $10K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 3,227 | $9K |
| 72158 | <1% | 74 | $9K | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 93 | $9K |
| 82565 | <1% | 9,274 | $9K | |
| 83655 | <1% | 1,424 | $8K | |
| 97035 | <1% | 1,799 | $8K | |
| 93308 | <1% | 96 | $8K | |
| 20610 | <1% | 156 | $8K | |
| G0008 | Administration of influenza virus vaccine | <1% | 1,165 | $8K |
| 80076 | <1% | 3,033 | $8K | |
| 84550 | <1% | 7,081 | $8K | |
| 84100 | <1% | 17,672 | $8K | |
| 86364 | <1% | 1,361 | $8K | |
| 82784 | <1% | 1,568 | $8K | |
| 93225 | <1% | 410 | $8K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 291 | $8K |
| 83002 | <1% | 795 | $7K | |
| 70498 | <1% | 630 | $7K | |
| 72040 | <1% | 507 | $7K | |
| 84156 | <1% | 6,338 | $6K | |
| 86258 | <1% | 1,069 | $6K | |
| C9145 | Injection, aprepitant, (aponvie), 1 mg | <1% | 360 | $6K |
| 82950 | <1% | 2,850 | $6K | |
| 88304 | <1% | 2,651 | $6K | |
| 10060 | <1% | 76 | $6K | |
| 99221 | <1% | 124 | $6K | |
| 43450 | <1% | 30 | $6K | |
| 29505 | <1% | 88 | $6K | |
| 82670 | <1% | 439 | $6K | |
| 87088 | <1% | 2,180 | $6K | |
| 77300 | <1% | 43 | $6K | |
| 76885 | <1% | 142 | $6K | |
| 86769 | <1% | 171 | $5K | |
| G0297 | Low dose ct scan (ldct) for lung cancer screening | <1% | 157 | $5K |
| 87640 | <1% | 539 | $5K | |
| 87899 | <1% | 831 | $5K | |
| 82247 | <1% | 2,243 | $5K | |
| 76000 | <1% | 779 | $5K | |
| 84460 | <1% | 3,654 | $5K | |
| 86870 | <1% | 57 | $5K | |
| 84450 | <1% | 3,604 | $5K | |
| 84134 | <1% | 1,151 | $5K | |
| 87641 | <1% | 537 | $5K | |
| 87205 | <1% | 5,264 | $5K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 11,993 | $5K |
| 82550 | <1% | 12,522 | $5K | |
| 81003 | <1% | 31,814 | $5K | |
| 72131 | <1% | 128 | $4K | |
| 80069 | <1% | 1,257 | $4K | |
| 80164 | <1% | 1,472 | $4K | |
| 83020 | <1% | 4,404 | $4K | |
| 86430 | <1% | 1,612 | $4K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 40,841 | $4K |
| 83690 | <1% | 34,432 | $4K | |
| 73080 | <1% | 1,066 | $4K | |
| 84703 | <1% | 8,004 | $4K | |
| 86901 | <1% | 16,929 | $4K | |
| 85652 | <1% | 4,734 | $4K | |
| 85730 | <1% | 9,420 | $4K | |
| 74183 | <1% | 26 | $4K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 497 | $4K |
| 82378 | <1% | 787 | $4K | |
| 84480 | <1% | 726 | $4K | |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | <1% | 16 | $4K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 24,255 | $4K |
| 73590 | <1% | 1,503 | $4K | |
| 73140 | <1% | 960 | $4K | |
| 82105 | <1% | 590 | $4K | |
| 82330 | <1% | 5,490 | $4K | |
| 95886 | <1% | 3,130 | $4K | |
| 84425 | <1% | 462 | $4K | |
| 83021 | <1% | 635 | $4K | |
| 97014 | <1% | 472 | $3K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 4,138 | $3K |
| 84520 | <1% | 2,338 | $3K | |
| 86160 | <1% | 492 | $3K | |
| 83615 | <1% | 4,971 | $3K | |
| 71101 | <1% | 505 | $3K | |
| 93923 | <1% | 66 | $3K | |
| 87634 | <1% | 155 | $3K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 39 | $3K |
| 82951 | <1% | 509 | $3K | |
| 84402 | <1% | 234 | $3K | |
| 83993 | <1% | 338 | $3K | |
| 88142 | <1% | 272 | $3K | |
| L4350 | Ankle control orthosis, stirrup style, rigid, includes any type interface (e.g., pneumatic, gel), prefabricated, off-the-shelf | <1% | 60 | $3K |
| 86200 | <1% | 487 | $3K | |
| 82274 | <1% | 514 | $3K | |
| 81025 | <1% | 40,163 | $2K | |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 970 | $2K |
| C8925 | Transesophageal echocardiography (tee) with contrast, or without contrast followed by with contrast, real time with image documentation (2d) (with or without m-mode recording); including probe placement, image acquisition, interpretation and report | <1% | 13 | $2K |
| 72170 | <1% | 973 | $2K | |
| 82150 | <1% | 2,920 | $2K | |
| 93798 | <1% | 41 | $2K | |
| 87040 | <1% | 6,952 | $2K | |
| G0109 | Diabetes outpatient self-management training services, group session (2 or more), per 30 minutes | <1% | 82 | $2K |
| 77290 | <1% | 12 | $2K | |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 53 | $2K |
| 73090 | <1% | 1,255 | $2K | |
| 82140 | <1% | 1,408 | $2K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 3,685 | $2K |
| 87493 | <1% | 296 | $2K | |
| 94729 | <1% | 2,040 | $2K | |
| 80197 | <1% | 325 | $2K | |
| J0585 | Injection, onabotulinumtoxina, 1 unit | <1% | 12 | $2K |
| 80051 | <1% | 859 | $2K | |
| 76641 | <1% | 39 | $2K | |
| 86235 | <1% | 113 | $2K | |
| 74022 | <1% | 3,221 | $2K | |
| 97033 | <1% | 228 | $2K | |
| 82533 | <1% | 282 | $2K | |
| 72146 | <1% | 16 | $2K | |
| 86706 | <1% | 371 | $2K | |
| 84165 | <1% | 442 | $2K | |
| 87046 | <1% | 607 | $2K | |
| 85046 | <1% | 1,752 | $2K | |
| 87045 | <1% | 607 | $2K | |
| 86765 | <1% | 469 | $2K | |
| 93350 | <1% | 12 | $2K | |
| 83013 | <1% | 51 | $2K | |
| 88104 | <1% | 236 | $1K | |
| 82785 | <1% | 194 | $1K | |
| 87015 | <1% | 766 | $1K | |
| 85651 | <1% | 1,799 | $1K | |
| 72156 | <1% | 13 | $1K | |
| 87075 | <1% | 924 | $1K | |
| 76604 | <1% | 153 | $1K | |
| 85379 | <1% | 5,874 | $1K | |
| 95819 | <1% | 14 | $1K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 5,198 | $1K |
| 93000 | <1% | 140 | $1K | |
| 97167 | <1% | 24 | $1K | |
| 73522 | <1% | 52 | $1K | |
| 84145 | <1% | 10,338 | $1K | |
| 73560 | <1% | 1,044 | $1K | |
| 86147 | <1% | 37 | $1K | |
| 86403 | <1% | 1,262 | $1K | |
| Q9969 | Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose | <1% | 308 | $1K |
| 83521 | <1% | 161 | $1K | |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 14 | $1K |
| 84484 | <1% | 40,796 | $1K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 17 | $990.58 |
| 76818 | <1% | 17 | $990.42 | |
| 90715 | <1% | 2,953 | $943.44 | |
| 95806 | <1% | 12 | $892.65 | |
| 94010 | <1% | 1,166 | $892.53 | |
| 87328 | <1% | 215 | $890.34 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 54,209 | $852.90 |
| 85018 | <1% | 2,074 | $848.22 | |
| 86787 | <1% | 234 | $808.45 | |
| 87329 | <1% | 217 | $803.63 | |
| 87529 | <1% | 40 | $800.47 | |
| 86376 | <1% | 120 | $789.30 | |
| 86694 | <1% | 118 | $734.57 | |
| 99231 | Subsequent hospital care, per day, straightforward or low complexity | <1% | 52 | $703.68 |
| 86304 | <1% | 163 | $683.86 | |
| 73552 | <1% | 314 | $680.53 | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 184 | $678.76 |
| 84132 | <1% | 4,706 | $667.60 | |
| 82952 | <1% | 366 | $649.23 | |
| 82553 | <1% | 8,970 | $632.96 | |
| 84155 | <1% | 506 | $622.49 | |
| 93320 | <1% | 1,319 | $611.88 | |
| 86225 | <1% | 100 | $602.51 | |
| G0009 | Administration of pneumococcal vaccine | <1% | 93 | $602.00 |
| 84590 | <1% | 181 | $598.87 | |
| 82077 | <1% | 11,552 | $588.22 | |
| 86920 | <1% | 686 | $546.95 | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 14 | $539.41 |
| 29125 | <1% | 1,044 | $508.60 | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 53 | $497.88 |
| 82805 | <1% | 3,743 | $446.34 | |
| 88184 | <1% | 12 | $445.93 | |
| 0001A | <1% | 14 | $426.35 | |
| 51798 | <1% | 2,074 | $418.77 | |
| 90656 | <1% | 24 | $411.75 | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 18 | $392.11 |
| 94760 | <1% | 22,703 | $391.32 | |
| 84144 | <1% | 38 | $378.72 | |
| 93226 | <1% | 319 | $368.30 | |
| 83605 | <1% | 18,991 | $351.75 | |
| J0558 | Injection, penicillin g benzathine and penicillin g procaine, 100,000 units | <1% | 12 | $333.85 |
| 82977 | <1% | 129 | $330.33 | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 15 | $304.87 |
| 86665 | <1% | 34 | $301.93 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 34,927 | $294.87 |
| 87209 | <1% | 99 | $293.41 | |
| 12002 | <1% | 683 | $278.83 | |
| 87177 | <1% | 98 | $274.66 | |
| 73060 | <1% | 172 | $271.60 | |
| 85384 | <1% | 2,063 | $271.08 | |
| 84630 | <1% | 70 | $253.35 | |
| 80178 | <1% | 113 | $248.10 | |
| 86696 | <1% | 38 | $247.83 | |
| 80177 | <1% | 83 | $240.98 | |
| 70360 | <1% | 80 | $238.09 | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 24 | $237.65 |
| 88302 | <1% | 255 | $224.55 | |
| J3490 | Unclassified drugs | <1% | 49,063 | $212.75 |
| 86800 | <1% | 26 | $208.29 | |
| 86923 | <1% | 52 | $204.57 | |
| 73562 | <1% | 15 | $191.68 | |
| 86704 | <1% | 42 | $185.29 | |
| 83014 | <1% | 51 | $177.84 | |
| 93325 | <1% | 1,452 | $177.81 | |
| 12011 | <1% | 995 | $172.00 | |
| 12001 | <1% | 1,643 | $172.00 | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 2,369 | $171.45 |
| 86695 | <1% | 38 | $169.81 | |
| 82310 | <1% | 82 | $169.13 | |
| 85014 | <1% | 507 | $165.77 | |
| 82040 | <1% | 125 | $162.41 | |
| G0123 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision | <1% | 16 | $158.34 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 14,775 | $148.87 |
| 97012 | <1% | 24 | $147.99 | |
| 87252 | <1% | 12 | $147.40 | |
| 83525 | <1% | 24 | $145.74 | |
| 82575 | <1% | 40 | $143.17 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 34,657 | $138.65 |
| 82627 | <1% | 13 | $134.00 | |
| 86039 | <1% | 26 | $128.40 | |
| 85613 | <1% | 40 | $127.40 | |
| 83930 | <1% | 609 | $125.03 | |
| 82731 | <1% | 12 | $123.16 | |
| 94664 | <1% | 5,257 | $112.30 | |
| 84295 | <1% | 3,403 | $108.44 | |
| 82088 | <1% | 12 | $107.38 | |
| 85576 | <1% | 90 | $107.34 | |
| 86677 | <1% | 15 | $102.64 | |
| 94799 | <1% | 8,154 | $99.14 | |
| Q9957 | Injection, perflutren lipid microspheres, per ml | <1% | 1,655 | $98.28 |
| 82010 | <1% | 2,113 | $88.79 | |
| 85460 | <1% | 1,379 | $80.29 | |
| 84466 | <1% | 14 | $77.73 | |
| J2704 | Injection, propofol, 10 mg | <1% | 18,589 | $76.00 |
| 82103 | <1% | 15 | $69.10 | |
| 94150 | <1% | 1,062 | $68.93 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 15,488 | $64.23 |
| 73660 | <1% | 24 | $63.21 | |
| 93041 | <1% | 726 | $56.82 | |
| 83630 | <1% | 41 | $55.42 | |
| 89051 | <1% | 144 | $54.66 | |
| 84244 | <1% | 12 | $54.29 | |
| 86255 | <1% | 27 | $51.59 | |
| 82270 | <1% | 31 | $46.83 | |
| 82747 | <1% | 12 | $42.56 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 17,699 | $41.63 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 21,698 | $41.11 |
| 85660 | <1% | 13 | $38.02 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 2,832 | $36.51 |
| 83520 | <1% | 15 | $35.88 | |
| 96376 | <1% | 11,230 | $34.32 | |
| 80143 | <1% | 1,333 | $34.27 | |
| 51702 | <1% | 1,539 | $29.64 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 677 | $28.42 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 1,476 | $25.05 |
| 83090 | <1% | 14 | $24.68 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 8,974 | $20.48 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 14,241 | $19.12 |
| 77002 | <1% | 81 | $15.85 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 10,472 | $13.08 |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 3,726 | $12.31 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 2,934 | $11.31 |
| 80179 | <1% | 1,196 | $11.09 | |
| J0280 | Injection, aminophyllin, up to 250 mg | <1% | 349 | $10.00 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 9,709 | $9.04 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 1,628 | $8.12 |
| 82375 | <1% | 27 | $6.94 | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 2,488 | $6.07 |
| A9270 | Non-covered item or service | <1% | 22,756 | $5.95 |
| 82435 | <1% | 3,326 | $5.55 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 4,040 | $3.48 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 10,109 | $2.50 |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 3,003 | $0.57 |
| J3535 | Drug administered through a metered dose inhaler | <1% | 58 | $0.52 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 19,298 | $0.39 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 4,185 | $0.21 |
| C1751 | Catheter, infusion, inserted peripherally, centrally or midline (other than hemodialysis) | 0% | 779 | $0.00 |
| J1756 | Injection, iron sucrose, 1 mg | 0% | 3,084 | $0.00 |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | 0% | 3,754 | $0.00 |
| 76937 | 0% | 100 | $0.00 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 1,157 | $0.00 |
| J1644 | Injection, heparin sodium, per 1000 units | 0% | 6,632 | $0.00 |
| 82800 | 0% | 844 | $0.00 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 5,456 | $0.00 |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 0% | 255 | $0.00 |
| J3370 | Injection, vancomycin hcl, 500 mg | 0% | 1,600 | $0.00 |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | 0% | 131 | $0.00 |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | 0% | 694 | $0.00 |
| J1245 | Injection, dipyridamole, per 10 mg | 0% | 320 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 232 | $0.00 |
| 0353U | 0% | 875 | $0.00 | |
| A9537 | Technetium tc-99m mebrofenin, diagnostic, per study dose, up to 15 millicuries | 0% | 73 | $0.00 |
| 3078F | 0% | 1,075 | $0.00 | |
| 88173 | 0% | 40 | $0.00 | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 1,157 | $0.00 |
| 76981 | 0% | 193 | $0.00 | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 84 | $0.00 |
| C1758 | Catheter, ureteral | 0% | 24 | $0.00 |
| J3250 | Injection, trimethobenzamide hcl, up to 200 mg | 0% | 158 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 281 | $0.00 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 128 | $0.00 |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | 0% | 331 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 700 | $0.00 |
| 85347 | 0% | 75 | $0.00 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 559 | $0.00 |
| 76942 | 0% | 153 | $0.00 | |
| J1953 | Injection, levetiracetam, 10 mg | 0% | 234 | $0.00 |
| A9541 | Technetium tc-99m sulfur colloid, diagnostic, per study dose, up to 20 millicuries | 0% | 43 | $0.00 |
| J0737 | Injection, clindamycin phosphate (baxter), not therapeutically equivalent to j0736, 300 mg | 0% | 65 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 278 | $0.00 |
| C1729 | Catheter, drainage | 0% | 250 | $0.00 |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | 0% | 188 | $0.00 |
| J2004 | Injection, lidocaine hcl with epinephrine, 1 mg | 0% | 66 | $0.00 |
| 97150 | Therapeutic procedure(s), group (2 or more individuals) | 0% | 12 | $0.00 |
| 86922 | 0% | 38 | $0.00 | |
| C1776 | Joint device (implantable) | 0% | 38 | $0.00 |
| 93356 | 0% | 26 | $0.00 | |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 319 | $0.00 |
| A4556 | Electrodes, (e.g., apnea monitor), per pair | 0% | 919 | $0.00 |
| 96368 | 0% | 861 | $0.00 | |
| J7999 | Compounded drug, not otherwise classified | 0% | 5,798 | $0.00 |
| J3360 | Injection, diazepam, up to 5 mg | 0% | 368 | $0.00 |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | 0% | 746 | $0.00 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | 0% | 613 | $0.00 |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | 0% | 1,438 | $0.00 |
| C1769 | Guide wire | 0% | 1,249 | $0.00 |
| 0352U | 0% | 1,711 | $0.00 | |
| J3411 | Injection, thiamine hcl, 100 mg | 0% | 371 | $0.00 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 2,861 | $0.00 |
| 94660 | 0% | 108 | $0.00 | |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | 0% | 248 | $0.00 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 0% | 383 | $0.00 |
| J1626 | Injection, granisetron hydrochloride, 100 mcg | 0% | 712 | $0.00 |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | 0% | 254 | $0.00 |
| 3075F | 0% | 86 | $0.00 | |
| 3079F | 0% | 220 | $0.00 | |
| 3074F | 0% | 1,074 | $0.00 | |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 179 | $0.00 |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | 0% | 102 | $0.00 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 87 | $0.00 |
| 0346T | 0% | 96 | $0.00 | |
| J2805 | Injection, sincalide, 5 micrograms | 0% | 49 | $0.00 |
| 82945 | 0% | 29 | $0.00 | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | 0% | 97 | $0.00 |
| J1940 | Injection, furosemide, up to 20 mg | 0% | 168 | $0.00 |
| 29130 | 0% | 56 | $0.00 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 469 | $0.00 |
| 86921 | 0% | 58 | $0.00 | |
| 3008F | 0% | 79 | $0.00 | |
| 36416 | 0% | 19 | $0.00 | |
| 64402 | 0% | 20 | $0.00 | |
| 84157 | 0% | 41 | $0.00 | |
| A4217 | Sterile water/saline, 500 ml | 0% | 143 | $0.00 |
| 0240U | 0% | 28 | $0.00 | |
| J1250 | Injection, dobutamine hydrochloride, per 250 mg | 0% | 12 | $0.00 |
| 88185 | 0% | 18 | $0.00 | |
| 96377 | 0% | 16 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMAINE, MARGARET (DIRECTOR)
| Provider | Location | Paid |
|---|---|---|
| Covenant Medical Center, INC. | Saginaw, MI | $14.75M |
| Covenant Medical Center, INC. | Saginaw, MI | $10.97M |
| Covenant Medical Center, INC. | Saginaw, MI | $5.99M |
| Covenant Medical Center, INC. | Saginaw, MI | $47K |
| Covenant Medical Center, INC | Saginaw, MI | $26K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.